- BACKGROUND: Biliary fistulas typically occur as surgical complications after laparoscopic cholecystectomy, liver transplantation, or partial liver resection. AIMS: This study aimed to evaluate the efficacy of the endoscopic treatment of biliary fistulae secondary to liver transplantation compared to that of other etiologies. METHODS: A retrospective study of 25 patients undergoing endoscopic retrograde cholangiopancreatography for biliary fistula from 2015 to 2021 was conducted at the Endoscospy Unit of Walter Cantídio University Hospital. Clinical characteristics and endoscopic success rates of the post-liver transplantation group were analyzed in comparison with those of other etiologies. RESULTS: The main causes of biliary fistula were liver transplantation (44%) and cholecystectomy complications (44%). The post-liver transplantation group had a significantly higher proportion of male sex (liver transplantation=81.8%, others=28.6%) and older age (liver transplantation=54.1 years, others=42.0 years) and a higher incidence of biliary stenosis (liver transplantation=90.9%, others=14.3%) than those of the group with other etiologies (p<0.05). The two groups received similar treatment types, among which sphincterotomy associated with biliary stent placement was most commonly used. Endoscopic therapeutic success rates showed no significant difference between the post-liver transplantation group (63.6%) and the group with other etiologies (71.4%). CONCLUSIONS: The endoscopic treatment of biliary fistulae secondary to liver transplantation presented a recovery rate similar to that of other etiologies despite the patients older age and the presence of biliary stenosis
Background and study aims: Malignant gastric outlet obstruction (MGOO) is a debilitating condition requiring effective palliation. Surgical gastrojejunostomy (SGJ) has been the traditional standard but is associated with relevant morbidity. Endoscopic ultrasound–guided gastroenterostomy (EUS-GE) has emerged as a minimally invasive alternative, though comparative efficacy and safety remain incompletely defined. This systematic review and meta-analysis compared EUS-GE and SGJ for palliative management of MGOO. Methods: This review was registered in PROSPERO (CRD420261283768). MEDLINE, Embase, Cochrane CENTRAL, Scopus, and LILACS were searched from January 2015 to October 2025. Random-effects meta-analyses were performed using risk ratios for technical and clinical success, odds ratios for adverse events, serious adverse events, symptom recurrence, reintervention, and 30-day mortality, and mean differences for length of hospital stay. Prespecified subgroup and sensitivity analyses were conducted to assess the robustness of findings. Results: Ten studies (2 randomized trials and 8 observational studies) including 1,087 patients (659 EUS-GE, 428 SGJ) were analyzed. Technical success was comparable between groups. EUS-GE was associated with higher clinical success (RR 1.06; 95% CI 1.01–1.12), fewer overall AE (OR 0.35; 95% CI 0.22–0.56) and SAE (OR 0.52; 95% CI 0.28–0.93). EUS-GE resulted in lower symptom recurrence (OR 0.39; 95% CI 0.18–0.85) and shorter LOS (mean difference −4.11 days; 95% CI −5.29 to −2.92). Reintervention rates and 30-day mortality were similar. Conclusions: EUS-GE is a safe and effective minimally invasive alternative to SGJ for palliation of MGOO. These findings support the growing role of EUS-GE as a preferred palliative strategy in specialized centers.